Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Sunscreen Decision Deadlines, Expedited TEAs Proposed

This article was originally published in The Tan Sheet

Executive Summary

The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.

You may also be interested in...



Sunscreen TEA Review Deadlines In Limbo In House, Default Approvals Cut

The House Energy and Commerce Health subcommittee unanimously advances the Sunscreen Innovation Act to full committee, but provisions in the bill seeking a tight timeline for FDA’s review of sunscreen ingredient TEAs are in limbo, according to the Public Access to Sunscreens coalition of stakeholders.

Sunscreen TEA Review Deadlines In Limbo In House, Default Approvals Cut

The House Energy and Commerce Health subcommittee unanimously advances the Sunscreen Innovation Act to full committee, but provisions in the bill seeking a tight timeline for FDA’s review of sunscreen ingredient TEAs are in limbo, according to the Public Access to Sunscreens coalition of stakeholders.

EWG Seeks Realistic FDA Review Deadlines In Sunscreen Innovation Act

While the Environmental Working Group supports the Sunscreen Innovation Act, it would like to see realistic deadlines put in place to accelerate FDA’s review of sunscreen-ingredient time-and-extent applications without including a default mechanism that would grant free market access to certain sunscreen actives when FDA fails to act within allotted timeframes.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel